News
New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...
20h
Zacks Investment Research on MSNOncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.83 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results